Valneva's Encouraging Findings on Lyme Disease Vaccine Candidate
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA) recently revealed encouraging results from its Phase 2 study for the Lyme disease vaccine candidate, VLA15. This pivotal study, identified as VLA15-221, showcased an impressive immunogenic profile and safety data after six months of the third booster dose across various age groups. The findings reaffirm the vaccine's effectiveness in generating strong immune responses in individuals after a yearly vaccination ahead of the Lyme season.
Robust Immune Response Confirmed
After the completion of the Phase 2 study, it was demonstrated that antibody levels remained significantly elevated beyond baseline for all six serotypes assessed, six months following the third booster dose. This persistence of antibody response is not only crucial for evaluating the vaccine's effectiveness but also confirms the significance of annual vaccinations to combat Lyme disease effectively.
Safety Profile Endorsed by Independent Review
The independent Data Monitoring Committee (DMC) overseeing the study found no safety concerns across all participant age groups. This results in a high degree of confidence in the safety profile of VLA15, paving the way for its potential future availability as a preventive measure against Lyme disease.
Background on Lyme Disease and Need for Vaccination
With Lyme disease being the most prevalent vector-borne illness in the Northern Hemisphere, the need for an approved vaccine has become increasingly urgent. The Centers for Disease Control and Prevention (CDC) estimates that nearly half a million individuals in the United States are diagnosed with Lyme disease each year, with cases also reported in Europe. The annual spike in cases calls for an effective vaccine, which VLA15 aims to fulfill.
The Collaboration with Pfizer
Valneva's collaboration with Pfizer, initiated in April 2020, has been pivotal in the advancement of VLA15. With the completion of vaccinations for the pivotal VALOR Phase 3 trial underway, the focus now shifts to interpreting the results and preparing for regulatory submissions. Should the Phase 3 data mirror these positive results, Valneva anticipates submitting a Biologics License Application (BLA) to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).
Details of the Phase 2 Study
The VLA15-221 study involved a robust design, enrolling 560 healthy participants aged 5 to 17 years. Participants received either the vaccine or a placebo in specified schedules. A critical measure of the study was the antibody persistence, which was monitored up to six months after the final booster was provided. Results showed the three-dose regimen effectively maintained higher antibody levels compared to two-dose schedules, indicating a strong rationale for this vaccination approach.
Valneva's Commitment to Infectious Disease Solutions
Valneva is firmly positioned as a specialty vaccine company. It focuses on developing vaccines for infectious diseases that address significant unmet medical needs. Known for its innovative strategies, Valneva emphasizes advancing its vaccine portfolio, which includes progress on the only Lyme disease vaccine candidate in advanced clinical development.
Looking Ahead
As Lyme disease cases rise globally, Valneva’s commitment to delivering a safe and effective vaccine becomes even more critical. The ongoing studies and positive results not only bolster the prospects for VLA15 but also signify hope for individuals in Lyme-endemic regions. Through collaboration and innovation, Valneva aims to contribute substantially to public health by offering effective vaccination against Lyme disease.
Frequently Asked Questions
What is VLA15?
VLA15 is a Lyme disease vaccine candidate developed by Valneva SE, which aims to provide immunity against Lyme disease through immunization.
What were the key results from the Phase 2 study of VLA15?
The Phase 2 study showed robust anamnestic immune responses and a favorable safety profile across various age groups six months after the vaccination.
What role does Pfizer play in the development of VLA15?
Valneva has partnered with Pfizer for the development and commercialization of VLA15, striving to bring this vaccine to market pending successful Phase 3 trials.
How prevalent is Lyme disease?
Lyme disease is the most common vector-borne illness in the Northern Hemisphere, with around 476,000 cases reported annually in the U.S. alone.
What is the next step for Valneva regarding VLA15?
After the completion of the pivotal VALOR Phase 3 trial, Valneva plans to submit regulatory applications to the FDA and EMA for approval of VLA15.
